[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658863":3},{"organization":4,"outcomesModule":7,"designInfo":34,"detailedDescription":37,"studyPopulation":38,"armGroups":39,"interventions":33,"overallOfficials":43,"centralContacts":48,"locations":33,"responsibleParty":54,"collaborators":33,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":33,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":33,"enrollmentInfo":67,"targetDuration":33,"studyType":70,"phases":33,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":81,"whyStopped":33,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":33},{"fullName":5,"class":6},"Assiut University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":33},[9],{"measure":10,"description":11,"timeFrame":12},"Sensitivity of non-contrast MRI for detection of hepatic metastases","Sensitivity of the non-contrast abbreviated MRI protocol for detection of hepatic metastases, using contrast-enhanced MSCT as the reference standard.","Baseline",[14,17,20,23,26,29],{"measure":15,"description":16,"timeFrame":12},"Sensitivity of contrast-enhanced MRI for detection of hepatic metastases","Sensitivity of the contrast-enhanced MRI protocol for detection of hepatic metastases, using contrast-enhanced MSCT as the reference standard.",{"measure":18,"description":19,"timeFrame":12},"Specificity of non-contrast MRI","Specificity of the non-contrast abbreviated MRI protocol for detection of hepatic metastases.",{"measure":21,"description":22,"timeFrame":12},"Specificity of contrast-enhanced MRI","Specificity of the contrast-enhanced MRI protocol for detection of hepatic metastases.",{"measure":24,"description":25,"timeFrame":12},"Number of hepatic lesions detected by non-contrast MRI","Mean number of hepatic metastatic lesions detected by the non-contrast MRI protocol.",{"measure":27,"description":28,"timeFrame":12},"Number of hepatic lesions detected by contrast-enhanced MRI","Mean number of hepatic metastatic lesions detected by the contrast-enhanced MRI protocol.",{"measure":30,"description":31,"timeFrame":32},"Proportion of patients with partial response according to RECIST 1.1","Proportion of patients classified as partial response according to RECIST 1.1 on follow-up MRI.","At 3 months",null,{"allocation":33,"interventionModel":33,"interventionModelDescription":33,"primaryPurpose":33,"observationalModel":35,"timePerspective":36,"maskingInfo":33},"CASE_ONLY","PROSPECTIVE","Accurate detection and follow-up of colorectal liver metastases are essential for staging and treatment planning. This observational study will include patients with histologically confirmed colorectal adenocarcinoma and suspected hepatic metastases.\n\nEach participant will undergo a non-contrast abbreviated MRI protocol followed by a contrast-enhanced MRI protocol using Gadodiamide during the same examination. Contrast-enhanced MSCT of the abdomen will serve as the reference standard. Treatment response will be assessed according to RECIST 1.1 on follow-up MRI.","Patients with histologically confirmed colorectal adenocarcinoma and suspected hepatic metastases referred to the Diagnostic and Interventional Radiology Department at Assiut University Hospitals.",[40],{"label":41,"type":33,"description":42,"interventionNames":33},"Single cohort: Patients with Colorectal Liver Metastases","Patients with confirmed colorectal adenocarcinoma and suspected hepatic metastases who will undergo both non-contrast and contrast-enhanced MRI protocols during the same examination.",[44],{"name":45,"affiliation":46,"role":47},"Amr F Mourad, prof","Diagnostic and Interventional Radiology Department, Assiut University Hospitals","STUDY_CHAIR",[49],{"name":50,"role":51,"phone":52,"phoneExt":33,"email":53},"Mina M William, Resident","CONTACT","01273242181","mina.18313293@med.aun.edu.eg",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"PRINCIPAL_INVESTIGATOR","Mina Mohsen William Basta","Resident Physician, Department of Diagnostic and Interventional Radiology","100658863","non-contrast-versus-contrast-enhanced-mri-in-colorectal-liver-metastases-100658863",false,"NCT07857317","Non-Contrast Versus Contrast-Enhanced MRI in Colorectal Liver Metastases","Comparative Evaluation of a Non-Contrast Abbreviated MRI Protocol and a Contrast-Enhanced MRI Protocol in Colorectal Liver Metastases","Inclusion Criteria:\n\n* \\- Histologically confirmed colorectal adenocarcinoma\n* One or more hepatic focal lesions known or suspected to represent colorectal liver metastases\n* Adequate image quality allowing reliable assessment of hepatic lesions\n* Patients scheduled to receive chemotherapy allowing assessment of treatment response\n* Patients referred for initial staging, restaging, or evaluation of treatment response\n* Written informed consent\n\nExclusion Criteria:\n\n* \\- Contraindications to gadolinium-based contrast administration\n* Incomplete MRI examinations\n* Inadequate image quality preventing reliable assessment\n* Contraindications to MRI examination","ALL","18 Years",{"count":68,"type":69},40,"ESTIMATED","OBSERVATIONAL","This prospective study aims to compare the diagnostic performance of a non-contrast abbreviated MRI protocol with a contrast-enhanced MRI protocol for the detection and follow-up assessment of colorectal liver metastases.",[73,74],"Liver Metastases","Liver Neoplasms",[76,77,78,79,80],"Colorectal liver metastases","Abbreviated MRI","Non-contrast MRI","Gadodiamide","Assiut","NOT_YET_RECRUITING","2026-10-01",{"date":84,"type":85},"2026-10-05","ACTUAL",{"date":87,"type":69},"2026-09-27",{"date":89,"type":69},"2028-03-20",{"name":5,"class":6}]